Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

Background and purpose In the phase 3b, randomized, double‐blind, placebo‐controlled
DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults …

Background To verify the long-term (24-week) efficacy, safety, and tolerability of
fremanezumab in real-life patients with high-frequency episodic migraine (HFEM:≥ 8 …

Objective The relative effects of monoclonal antibody against calcitonin gene-related
peptide (CGRP) or its receptor for adult migraine patients with prior treatment failure remains …

Migraine is a leading cause of disability worldwide. A minority of individuals with migraine
develop resistant or refractory conditions characterised by≥ 8 monthly days of debilitating …

Objective To provide a position statement update from The American Headache Society
specifically regarding therapies targeting calcitonin gene‐related peptide (CGRP) for the …

Abstract Purpose of Review Despite the unmet therapeutic needs of patients with chronic
migraine (CM) and/or medication overuse, available treatment options are limited. Recently …

Background The multinational phase 3b DELIVER trial was designed to evaluate the
efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive …